We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
NoNO Inc. is a privately held, Canadian biotech developing neurotherapeutics for acute and chronic CNS disease. Our lead product is in two Phase 3 acute stroke studies – ESCAPE NA-1 for endovascular stroke therapy patients in the hospital and FRONTIER for treatment of suspected stroke patients pre-hospital by paramedics. We have imminent pivotal data with our lead indication reading out in Q4 2019 followed by anticipated commercial launch in Q1 2021.
NA-1 is a first-in-class drug against a first-in-class target, PSD95, for the treatment of the leading cause of global neurological disability. The USFDA has granted Fast Track and Orphan designations. NoNO has a strong balance sheet and cash flow to achieve NDA clearance and to support R&D efforts for label expansion from acute to chronic CNS. We anticipate entering clinic for our first chronic CNS indication by the end of 2019.